Research and development

Our development pipeline

Veranschaulichung der Projektphasen

Phasen einer klinischen Entwicklung

Weitere Informationen

Biotest’s development projects involve new therapy options in indications with a particularly high medical need. Moreover, the focus is also on further developing already authorised medicines with the aim of opening up other areas of use or making administration easier and more comfortable for the patient. You will find a summary of our current research and development projects here.

By clicking on the name you will obtain further information about the individual projects.

Our development pipeline

Therapeutic Area

All

Haematology

Clinical immunology

Intensive care medicine

Active substance

Indication

Phase

Active substance & Indication

Phase

   
  • pre
  • 1
  • 2
  • 3
  • reg
  • launch
  • lcm
 

IgG Next Generation
BT-595

Primary Immune Deficiency (PID)

IgG Next Generation

BT-595
Primary Immune Deficiency (PID)

 

IgG Next Generation
BT-595

Idiopathic Thrombocytopenic Purpura (ITP)

IgG Next Generation

BT-595
Idiopathic Thrombocytopenic Purpura (ITP)

 

Fibrinogen
BT-524

Congenital fibrinogen deficiency

Fibrinogen

BT-524
Congenital fibrinogen deficiency

 

Fibrinogen
BT-524

Acquired Fibrinogen Deficiency

Fibrinogen

BT-524
Acquired Fibrinogen Deficiency

 

Cytotect 70
BT-084

Congenital CMV infection prophylaxis

Cytotect 70

BT-084
Congenital CMV infection prophylaxis

 

Trimodulin
BT-588

Severe community acquired pneumonia

Trimodulin

BT-588
Severe community acquired pneumonia

 

BT-063

Systemic lupus erythematosus

BT-063
Systemic lupus erythematosus

 

Indatuximab Ravtansine
BT-062

Multiple myeloma

Indatuximab Ravtansine

BT-062
Multiple myeloma

 

Indatuximab Ravtansine*
BT-062

Solid tumors

Indatuximab Ravtansine*

BT-062
Solid tumors

 

Tregalizumab
BT-061

other diseases

Tregalizumab

BT-061
other diseases